Compare MBRX & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBRX | MBAI |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | Israel |
| Employees | N/A | 85 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1M | 12.0M |
| IPO Year | 2016 | N/A |
| Metric | MBRX | MBAI |
|---|---|---|
| Price | $2.38 | $1.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $61.00 | N/A |
| AVG Volume (30 Days) | ★ 258.5K | 165.6K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $1.29 |
| 52 Week High | $7.98 | $3.92 |
| Indicator | MBRX | MBAI |
|---|---|---|
| Relative Strength Index (RSI) | 47.06 | 38.39 |
| Support Level | $2.16 | $1.30 |
| Resistance Level | $2.64 | $1.83 |
| Average True Range (ATR) | 0.20 | 0.12 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 19.40 | 4.85 |
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.